Literature DB >> 19032222

Rejection of cardiac xenografts transplanted from alpha1,3-galactosyltransferase gene-knockout (GalT-KO) pigs to baboons.

Y Hisashi1, K Yamada, K Kuwaki, Y-L Tseng, F J M F Dor, S L Houser, S C Robson, H-J Schuurman, D K C Cooper, D H Sachs, R B Colvin, A Shimizu.   

Abstract

The use of alpha1,3-galactosyltransferase gene-knockout (GalT-KO) swine donors in discordant xenotransplantation has extended the survival of cardiac xenografts in baboons following transplantation. Eight baboons received heterotopic cardiac xenografts from GalT-KO swine and were treated with a chronic immunosuppressive regimen. The pathologic features of acute humoral xenograft rejection (AHXR), acute cellular xenograft rejection (ACXR) and chronic rejection were assessed in the grafts. No hyperacute rejection developed and one graft survived up to 6 months after transplantation. However, all GalT-KO heart grafts underwent graft failure with AHXR, ACXR and/or chronic rejection. AHXR was characterized by interstitial hemorrhage and multiple thrombi in vessels of various sizes. ACXR was characterized by TUNEL(+) graft cell injury with the infiltration of T cells (including CD3 and TIA-1(+) cytotoxic T cells), CD4(+) cells, CD8(+) cells, macrophages and a small number of B and NK cells. Chronic xenograft vasculopathy, a manifestation of chronic rejection, was characterized by arterial intimal thickening with TUNEL(+) dead cells, antibody and complement deposition, and/or cytotoxic T-cell infiltration. In conclusion, despite the absence of the Gal epitope, acute and chronic antibody and cell-mediated rejection developed in grafts, maintained by chronic immunosupression, presumably due to de novo responses to non-Gal antigens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19032222      PMCID: PMC2836186          DOI: 10.1111/j.1600-6143.2008.02444.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  38 in total

Review 1.  Xenotransplantation.

Authors:  D H Sachs; M Sykes; S C Robson; D K Cooper
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

Review 2.  The cellular rejection of xenografts--recent insights.

Authors:  Fabien Sebille; Anthony Dorling; Robert I Lechler
Journal:  Xenotransplantation       Date:  2003-01       Impact factor: 3.907

3.  Acute humoral xenograft rejection: destruction of the microvascular capillary endothelium in pig-to-nonhuman primate renal grafts.

Authors:  A Shimizu; S M Meehan; T Kozlowski; T Sablinski; F L Ierino; D K Cooper; D H Sachs; R B Colvin
Journal:  Lab Invest       Date:  2000-06       Impact factor: 5.662

Review 4.  The challenge of rejection and cardiac allograft vasculopathy.

Authors:  W G Cotts; M R Johnson
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

Review 5.  Will the pig solve the transplantation backlog?

Authors:  David K C Cooper; Bernd Gollackner; David H Sachs
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

Review 6.  Prospects for xenotransplantation.

Authors:  J S Logan
Journal:  Curr Opin Immunol       Date:  2000-10       Impact factor: 7.486

Review 7.  Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: the present status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases.

Authors:  D K Cooper; A M Keogh; J Brink; P A Corris; W Klepetko; R N Pierson; M Schmoeckel; R Shirakura; L Warner Stevenson
Journal:  J Heart Lung Transplant       Date:  2000-12       Impact factor: 10.247

8.  Clinical xenotransplantion--how close are we?

Authors:  David K C Cooper
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

9.  Production of alpha 1,3-galactosyltransferase-deficient pigs.

Authors:  Carol J Phelps; Chihiro Koike; Todd D Vaught; Jeremy Boone; Kevin D Wells; Shu-Hung Chen; Suyapa Ball; Susan M Specht; Irina A Polejaeva; Jeff A Monahan; Pete M Jobst; Sugandha B Sharma; Ashley E Lamborn; Amy S Garst; Marilyn Moore; Anthony J Demetris; William A Rudert; Rita Bottino; Suzanne Bertera; Massimo Trucco; Thomas E Starzl; Yifan Dai; David L Ayares
Journal:  Science       Date:  2002-12-19       Impact factor: 47.728

10.  Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen.

Authors:  Kenji Kuwaki; Christoph Knosalla; Frank J M F Dor; Bernd Gollackner; Yau-Lin Tseng; Stuart Houser; Nicolas Mueller; Derek Prabharasuth; Amy Alt; Kathy Moran; Jane Cheng; Amir Behdad; David H Sachs; Jay A Fishman; Henk-Jan Schuurman; Michel Awwad; David K C Cooper
Journal:  Am J Transplant       Date:  2004-03       Impact factor: 8.086

View more
  30 in total

1.  Pathologic characteristics of transplanted kidney xenografts.

Authors:  Akira Shimizu; Kazuhiko Yamada; Simon C Robson; David H Sachs; Robert B Colvin
Journal:  J Am Soc Nephrol       Date:  2011-11-23       Impact factor: 10.121

2.  Preparation and physical properties of a novel biocompatible porcine corneal acellularized matrix.

Authors:  Yi Shao; Luowa Quyang; Yueping Zhou; Jing Tang; Yuehui Tan; Qiuping Liu; Zhirong Lin; Tingting Yin; Fangfang Qiu; Zuguo Liu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-06-09       Impact factor: 2.416

Review 3.  Which anti-platelet therapies might be beneficial in xenotransplantation?

Authors:  Moritz Schmelzle; Peter J Cowan; Simon C Robson
Journal:  Xenotransplantation       Date:  2011 Mar-Apr       Impact factor: 3.907

Review 4.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

5.  Human CD55 expression blocks hyperacute rejection and restricts complement activation in Gal knockout cardiac xenografts.

Authors:  Christopher G A McGregor; Davide Ricci; Naoto Miyagi; Paul G Stalboerger; Zeji Du; Elise A Oehler; Henry D Tazelaar; Guerard W Byrne
Journal:  Transplantation       Date:  2012-04-15       Impact factor: 4.939

6.  Complete absence of the αGal xenoantigen and isoglobotrihexosylceramide in α1,3galactosyltransferase knock-out pigs.

Authors:  Gisella L Puga Yung; Yunsen Li; Lubor Borsig; Anne-Laure Millard; Maria B Karpova; Dapeng Zhou; Jörg D Seebach
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

7.  First experience with the use of a recombinant CD3 immunotoxin as induction therapy in pig-to-primate xenotransplantation: the effect of T-cell depletion on outcome.

Authors:  Hiroaki Nishimura; Joseph Scalea; Zhirui Wang; Akira Shimizu; Shannon Moran; Bradford Gillon; David H Sachs; Kazuhiko Yamada
Journal:  Transplantation       Date:  2011-09-27       Impact factor: 4.939

8.  Rhesus monkeys and baboons develop clotting factor VIII inhibitors in response to porcine endothelial cells or islets.

Authors:  John M Stewart; Alice F Tarantal; Wayne J Hawthorne; Evelyn J Salvaris; Philip J O'Connell; Mark B Nottle; Anthony J F d'Apice; Peter J Cowan; Mary Kearns-Jonker
Journal:  Xenotransplantation       Date:  2014-05-08       Impact factor: 3.907

9.  Anti-inflammatory and anticoagulant effects of transgenic expression of human thrombomodulin in mice.

Authors:  S Crikis; X M Zhang; S Dezfouli; K M Dwyer; L M Murray-Segal; E Salvaris; C Selan; S C Robson; H H Nandurkar; P J Cowan; A J F d'Apice
Journal:  Am J Transplant       Date:  2010-01-06       Impact factor: 8.086

10.  Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons.

Authors:  Karen Kim; Christian Schuetz; Nahel Elias; Gregory R Veillette; Isaac Wamala; Manish Varma; R Neal Smith; Simon C Robson; A Benedict Cosimi; David H Sachs; Martin Hertl
Journal:  Xenotransplantation       Date:  2012 Jul-Aug       Impact factor: 3.907

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.